# MT-ATP6

## Overview
The MT-ATP6 gene is a critical component of the mitochondrial genome, encoding the mitochondrially encoded ATP synthase membrane subunit 6, a transmembrane protein integral to the function of ATP synthase, also known as Complex V. This protein is embedded in the inner mitochondrial membrane and plays a pivotal role in the process of oxidative phosphorylation, facilitating ATP production by forming a proton channel within the F_o domain of ATP synthase. The MT-ATP6 subunit is essential for the mechanical rotation of the enzyme's rotor, which is driven by proton translocation, ultimately leading to ATP synthesis. Mutations in the MT-ATP6 gene can disrupt these processes, leading to mitochondrial dysfunction and a spectrum of clinical disorders, including Leigh syndrome and neuropathy, ataxia, and retinitis pigmentosa (NARP) (Ganetzky2019MTATP6mitochondrial; MorenoLoshuertos2023A). Understanding the structure and function of MT-ATP6 is crucial for elucidating the molecular mechanisms underlying these mitochondrial diseases and developing potential therapeutic strategies.

## Structure
The MT-ATP6 gene encodes a hydrophobic polypeptide consisting of 226 amino acids, which is embedded in the inner mitochondrial membrane (IMM) and plays a critical role in ATP synthesis through the rotary catalysis of ATP synthase (Del2024Variants). The protein is part of the F_o sector of ATP synthase, interacting with the c8-ring and the central stalk formed by subunits γ, δ, and ε (Del2024Variants). 

The MT-ATP6 protein is characterized by multiple transmembrane α-helices, which are crucial for its function in proton translocation (MorenoLoshuertos2023A). These helices form a complex three-dimensional structure that integrates into the ATP synthase complex, facilitating the interaction with the c-ring to promote its rotation (MorenoLoshuertos2023A). 

Mutations in MT-ATP6, such as m.8993T > G, can introduce structural changes that affect the protein's function, such as altering the hydrophobic barrier and electrostatic environment, impacting proton discharge and c-ring rotation (Su2021The). These mutations can lead to significant reductions in ATP production and are linked to various mitochondrial disorders (MorenoLoshuertos2023A).

## Function
The MT-ATP6 gene encodes a subunit of the mitochondrial ATP synthase, also known as Complex V, which is essential for ATP production in human cells. This enzyme complex is responsible for the final step of oxidative phosphorylation, utilizing the proton gradient generated by the electron transport chain to synthesize ATP from ADP and inorganic phosphate (MorenoLoshuertos2023A; Trounce1994Cytoplasmic). The MT-ATP6 subunit is part of the Fo domain of ATP synthase, where it forms a proton channel that facilitates the flow of protons across the inner mitochondrial membrane. This proton translocation is coupled to the mechanical rotation of the enzyme's rotor, which drives the conformational changes necessary for ATP synthesis (Ganetzky2019MTATP6mitochondrial; Del2024Variants).

In healthy cells, MT-ATP6 is crucial for maintaining cellular energy levels, supporting various cellular functions such as cell proliferation and survival (MorenoLoshuertos2023A). The proper function of MT-ATP6 is vital for the stability and assembly of ATP synthase, ensuring efficient ATP production and maintaining the mitochondrial membrane potential (Nijtmans2001Impaired). This process is essential for energy metabolism and cellular respiration, impacting overall organismal health and function.

## Clinical Significance
Mutations in the MT-ATP6 gene are associated with a range of mitochondrial disorders, most notably Leigh syndrome and neuropathy, ataxia, and retinitis pigmentosa (NARP) (Ng2019Pathogenic; Ganetzky2019MTATP6mitochondrial). These conditions often present with neurological symptoms due to impaired ATP production. The m.8993T>G mutation is particularly associated with severe phenotypes like Leigh syndrome, characterized by neurodegeneration and metabolic strokes (Ganetzky2019MTATP6mitochondrial; Peretz2021Prospective).

MT-ATP6 mutations can also lead to other clinical manifestations, including peripheral neuropathy, spinocerebellar ataxia, and renal involvement such as IgA nephropathy (Ng2019Pathogenic; Kenvin2021Threshold). The phenotypic expression of these mutations is influenced by the level of heteroplasmy, with higher levels often correlating with more severe disease (Ganetzky2019MTATP6mitochondrial; Peretz2021Prospective).

The clinical spectrum of MT-ATP6-related disorders is broad, ranging from asymptomatic carriers to severe multi-systemic conditions. This variability is attributed to factors such as tissue-specific heteroplasmy and potential gene-gene interactions (Stendel2020Delineating; Capiau2022Clinical).

## Interactions
MT-ATP6, a subunit of the mitochondrial ATP synthase complex, plays a crucial role in oxidative phosphorylation. It is involved in the formation of the membrane domain of ATP synthase, interacting closely with other subunits to facilitate proton translocation and ATP synthesis. The MT-ATP6 protein interacts with the c-ring of ATP synthase, which is essential for the enzyme's rotor mechanism and proton flow (Del2024Variants). Variants in MT-ATP6 can disrupt these interactions, affecting the stability and function of ATP synthase, as seen in mutations that alter the interaction between subunit a and the c-ring, impacting proton translocation and ATP synthesis (MorenoLoshuertos2023A).

The MT-ATP6 subunit is also part of the membrane-bound rotor of ATP synthase, interacting with the central stalk and c-subunits, which are crucial for the enzyme's function (Spikes2020Structure). These interactions are vital for maintaining the structural integrity and function of ATP synthase, and disruptions can lead to mitochondrial dysfunction and associated diseases (Del2024Variants). Understanding these interactions is essential for elucidating the molecular mechanisms underlying mitochondrial disorders linked to MT-ATP6 mutations (Ng2021Translation).


## References


1. (Ng2021Translation) Translation of MT-ATP6 pathogenic variants reveals distinct regulatory consequences from the co-translational quality control of mitochondrial protein synthesis. This article has 0 citations.

[2. (MorenoLoshuertos2023A) Raquel Moreno-Loshuertos, Nieves Movilla, Joaquín Marco-Brualla, Ruth Soler-Agesta, Patricia Ferreira, José Antonio Enríquez, and Patricio Fernández-Silva. A mutation in mouse mt-atp6 gene induces respiration defects and opposed effects on the cell tumorigenic phenotype. International Journal of Molecular Sciences, 24(2):1300, January 2023. URL: http://dx.doi.org/10.3390/ijms24021300, doi:10.3390/ijms24021300. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24021300)

[3. (Peretz2021Prospective) Ryan H. Peretz, Nicholas Ah Mew, Hilary J. Vernon, and Rebecca D. Ganetzky. Prospective diagnosis of mt-atp6-related mitochondrial disease by newborn screening. Molecular Genetics and Metabolism, 134(1–2):37–42, September 2021. URL: http://dx.doi.org/10.1016/j.ymgme.2021.06.007, doi:10.1016/j.ymgme.2021.06.007. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2021.06.007)

[4. (Nijtmans2001Impaired) Leo G.J. Nijtmans, Nadine S. Henderson, Giuseppe Attardi, and Ian J. Holt. Impaired atp synthase assembly associated with a mutation in the human atp synthase subunit 6 gene. Journal of Biological Chemistry, 276(9):6755–6762, March 2001. URL: http://dx.doi.org/10.1074/jbc.m008114200, doi:10.1074/jbc.m008114200. This article has 97 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m008114200)

[5. (Ng2019Pathogenic) Yi Shiau Ng, Mika H. Martikainen, Gráinne S. Gorman, Alasdair Blain, Enrico Bugiardini, Apphia Bunting, Andrew M. Schaefer, Charlotte L. Alston, Emma L. Blakely, Sunil Sharma, Imelda Hughes, Albert Lim, Christian de Goede, Meriel McEntagart, Stefan Spinty, Iain Horrocks, Mark Roberts, Cathy E. Woodward, Patrick F. Chinnery, Rita Horvath, Victoria Nesbitt, Carl Fratter, Joanna Poulton, Michael G. Hanna, Robert D. S. Pitceathly, Robert W. Taylor, Doug M. Turnbull, and Robert McFarland. Pathogenic variants in mt‐atp6: a united kingdom–based mitochondrial disease cohort study. Annals of Neurology, 86(2):310–315, July 2019. URL: http://dx.doi.org/10.1002/ana.25525, doi:10.1002/ana.25525. This article has 33 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.25525)

[6. (Kenvin2021Threshold) Sebastian Kenvin, Ruben Torregrosa-Muñumer, Marco Reidelbach, Jana Pennonen, Jeremi J Turkia, Erika Rannila, Jouni Kvist, Markus T Sainio, Nadine Huber, Sanna-Kaisa Herukka, Annakaisa Haapasalo, Mari Auranen, Ras Trokovic, Vivek Sharma, Emil Ylikallio, and Henna Tyynismaa. Threshold of heteroplasmic truncating mt-atp6 mutation in reprogramming, notch hyperactivation and motor neuron metabolism. Human Molecular Genetics, 31(6):958–974, October 2021. URL: http://dx.doi.org/10.1093/hmg/ddab299, doi:10.1093/hmg/ddab299. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddab299)

[7. (Stendel2020Delineating) Claudia Stendel, Christiane Neuhofer, Elisa Floride, Shi Yuqing, Rebecca D. Ganetzky, Joohyun Park, Peter Freisinger, Cornelia Kornblum, Stephanie Kleinle, Ludger Schöls, Felix Distelmaier, Georg M. Stettner, Boriana Büchner, Marni J. Falk, Johannes A. Mayr, Matthis Synofzik, Angela Abicht, Tobias B. Haack, Holger Prokisch, Saskia B. Wortmann, Kei Murayama, Fang Fang, and Thomas Klopstock. Delineating mt-atp6 -associated disease: from isolated neuropathy to early onset neurodegeneration. Neurology Genetics, February 2020. URL: http://dx.doi.org/10.1212/NXG.0000000000000393, doi:10.1212/nxg.0000000000000393. This article has 78 citations.](https://doi.org/10.1212/NXG.0000000000000393)

[8. (Capiau2022Clinical) Sara Capiau, Joél Smet, Boel De Paepe, Yilmaz Yildiz, Mutluay Arslan, Olivier Stevens, Maxime Verschoore, Hedwig Stepman, Sara Seneca, and Arnaud Vanlander. Clinical heterogeneity in mt-atp6 pathogenic variants: same genotype—different onset. Cells, 11(3):489, January 2022. URL: http://dx.doi.org/10.3390/cells11030489, doi:10.3390/cells11030489. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11030489)

[9. (Trounce1994Cytoplasmic) I Trounce, S Neill, and D C Wallace. Cytoplasmic transfer of the mtdna nt 8993 t–&gt;g (atp6) point mutation associated with leigh syndrome into mtdna-less cells demonstrates cosegregation with a decrease in state iii respiration and adp/o ratio. Proceedings of the National Academy of Sciences, 91(18):8334–8338, August 1994. URL: http://dx.doi.org/10.1073/pnas.91.18.8334, doi:10.1073/pnas.91.18.8334. This article has 155 citations.](https://doi.org/10.1073/pnas.91.18.8334)

[10. (Spikes2020Structure) Tobias E. Spikes, Martin G. Montgomery, and John E. Walker. Structure of the dimeric atp synthase from bovine mitochondria. Proceedings of the National Academy of Sciences, 117(38):23519–23526, September 2020. URL: http://dx.doi.org/10.1073/pnas.2013998117, doi:10.1073/pnas.2013998117. This article has 155 citations.](https://doi.org/10.1073/pnas.2013998117)

[11. (Ganetzky2019MTATP6mitochondrial) Rebecca D. Ganetzky, Claudia Stendel, Elizabeth M. McCormick, Zarazuela Zolkipli-Cunningham, Amy C. Goldstein, Thomas Klopstock, and Marni J. Falk. Mt-atp6mitochondrial disease variants: phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases: ganetzky<scp>et al.</scp>. Human Mutation, 40(5):499–515, March 2019. URL: http://dx.doi.org/10.1002/humu.23723, doi:10.1002/humu.23723. This article has 75 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23723)

[12. (Su2021The) Xin Su, Alain Dautant, Malgorzata Rak, François Godard, Nahia Ezkurdia, Marine Bouhier, Maïlis Bietenhader, David M Mueller, Roza Kucharczyk, Jean-Paul di Rago, and Déborah Tribouillard-Tanvier. The pathogenic m.8993 t &amp;gt; g mutation in mitochondrial atp6 gene prevents proton release from the subunit c-ring rotor of atp synthase. Human Molecular Genetics, 30(5):381–392, February 2021. URL: http://dx.doi.org/10.1093/hmg/ddab043, doi:10.1093/hmg/ddab043. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddab043)

[13. (Del2024Variants) Valentina Del Dotto, Francesco Musiani, Alessandra Baracca, and Giancarlo Solaini. Variants in human atp synthase mitochondrial genes: biochemical dysfunctions, associated diseases, and therapies. International Journal of Molecular Sciences, 25(4):2239, February 2024. URL: http://dx.doi.org/10.3390/ijms25042239, doi:10.3390/ijms25042239. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25042239)